Regulus Therapeutics Inc (STU:7RG0)
€ 1.99 -0.1 (-4.81%) Market Cap: 132.67 Mil Enterprise Value: 44.51 Mil PE Ratio: 0 PB Ratio: 1.35 GF Score: 36/100

Regulus Therapeutics Inc at Oppenheimer Rare & Orphan Disease Summit (Virtual) Transcript

May 21, 2021 / 03:35PM GMT
Release Date Price: €7.55 (-1.95%)
Justin Alexander Kim
Oppenheimer & Co. Inc., Research Division - Associate

Good morning, everyone. Thanks for joining us today for Oppenheimer's Rare & Orphan Disease Day Conference. My name is Justin Kim. I'm one of the research analysts at Op Co. It's my pleasure to welcome the Regulus team, CEO, Mr. Jay Hagen, to give a presentation on the company. So please take it away, Jay.

Joseph P. Hagan
Regulus Therapeutics Inc. - President, CEO & Director

Thanks, Justin, and thanks to the team at Oppenheimer for including us in today's Rare & Orphan Disease Summit. We're pleased to be providing an update on our ADPKD program. That will be the main focus of the discussion here.

I will be making forward-looking statements. Actual results may differ materially from those expressed or implied today. I encourage investors to read risk factors associated with our business in our SEC filings, including our most recent 10-Q. Bear with me one second here, I've got the -- blocking by screen.

So in terms of recent highlights, we announced

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot